Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants

Authors: Sabine Heublein, Katinka Grasse, Harald Hessel, Alexander Burges, Miriam Lenhard, Jutta Engel, Thomas Kirchner, Udo Jeschke, Doris Mayr

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants, an extra ovarian spread occurring alongside the s-BOT in certain cases. It remains obscure whether these implants actually resemble metastasis owning the same genetic pattern as the ovarian primary or whether they develop independently.

Methods

The current study, in the aim of further clarifying the genetic origin of implants, assessed BRAF/KRAS hot spot mutations and the p53/p16INK4a immunophenotype of s-BOTs and corresponding implants (n = 49) of 15 patients by pyro-sequencing and immunostaining, respectively.

Results

A significant proportion of both s-BOTs and implants showed KRAS or BRAF mutation and though p16INK4a was found to be abundantly expressed, p53 immunoreactivity was rather low. When genotypes of BRAF/KRAS mutated s-BOTs and corresponding implants were compared no patient presented with a fully matching mutation profile of s-BOTs and all corresponding implants.

Conclusions

The current study reveals genetic heterogeneity of s-BOTs and implants, as none of the markers examined showed constant reciprocity. Hence, our findings may assist to explain the different clinical presentation of s-BOTs and implants and might encourage to applying more individualized follow up protocols.
Appendix
Available only for authorised users
Literature
1.
McCluggage WG: The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol. 2010, 22 (5): 462-472.CrossRefPubMed
2.
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG: Grading ovarian serous carcinoma using a two-tier system. Am j surg pathol. 2004, 28 (4): 496-504.CrossRefPubMed
3.
Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A: Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009, 145 (2): 189-194.CrossRefPubMed
4.
Silva EG, Gershenson DM, Malpica A, Deavers M: The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006, 30 (11): 1367-1371.CrossRefPubMed
5.
Kurman RJ, Seidman JD, Shih IM: Serous borderline tumours of the ovary. Histopathology. 2005, 47 (3): 310-315.CrossRefPubMed
6.
Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C: Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer. 1998, 83 (10): 2157-2163.CrossRefPubMed
7.
Seidman JD, Kurman RJ: Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000, 31 (5): 539-557.CrossRefPubMed
8.
Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Cote JF, Haie-Meder C, Duvillard P, et al: Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2003, 14 (4): 592-598.CrossRef
9.
Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005, 29 (6): 707-723.CrossRefPubMed
10.
Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, Lyon: IARC Press
11.
Mayr D, Hirschmann A, Lohrs U, Diebold J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006, 103 (3): 883-887.CrossRefPubMed
12.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007, 1773 (8): 1263-1284.CrossRefPubMed
13.
Radojicic J, Zaravinos A, Spandidos DA: HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers. 2012, 27 (1): 1-12.CrossRefPubMed
14.
15.
Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W: Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer J Int Du Cancer. 2009, 125 (7): 1698-1704.CrossRef
16.
Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA: Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994, 54 (11): 2914-2918.PubMed
17.
Soussi T: p53 alterations in human cancer: more questions than answers. Oncogene. 2007, 26 (15): 2145-2156.CrossRefPubMed
18.
Zong L, Chen P, Xu Y: Correlation between P53 expression and malignant risk of gastrointestinal stromal tumors: evidence from 9 studies. Eur J Surg Oncol J Eur Soc Surg Oncol British Assoc Surg Oncol. 2012, 38 (3): 189-195.
19.
Figarella Branger D, Maues De Paula A, Colin C, Bouvier C: Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Revue Neurol. 2011, 167 (10): 683-690.CrossRef
20.
Vereczkey I, Serester O, Dobos J, Gallai M, Szakacs O, Szentirmay Z, Toth E: Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res. 2011, 17 (3): 551-559.CrossRefPubMed
21.
Ziolkowska-Seta I, Madry R, Kraszewska E, Szymanska T, Timorek A, Rembiszewska A, Kupryjanczyk J: TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol. 2009, 112 (1): 179-184.CrossRefPubMed
22.
Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer res. 1991, 51 (11): 2979-2984.PubMed
23.
Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J: A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008, 47 (4): 600-607.CrossRefPubMed
24.
O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005, 29 (8): 1034-1041.PubMed
25.
Brustmann H: Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2007, 26 (2): 147-153.
26.
Giurgea LN, Ungureanu C, Mihailovici MS: The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryol Revue Roumaine De Morphol Et Embryol. 2012, 53 (4): 967-973.
27.
Remmele W, Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987, 8 (3): 138-140.PubMed
28.
Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, et al: The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. Int J Cancer J Int Du Cancer. 2012, 131 (4): 980-986.CrossRef
29.
Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009, 205 (12): 858-862.CrossRefPubMed
30.
Pothuri B, Leitao M, Barakat R, et al: Abstract in Society of Gynecologic Oncologists, 32nd Annual Meeting. Genetic Analysis of Ovarian Carcinoma Histogenesis. 2001
31.
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007, 31 (2): 161-169.CrossRefPubMed
32.
Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M: Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004, 64 (19): 6915-6918.CrossRefPubMed
33.
Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM, Shih Ie M: Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest. 2004, 84 (6): 778-784.CrossRefPubMed
34.
Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih Ie M: Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012, 226 (3): 413-420.CrossRefPubMed
35.
Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004, 164 (5): 1511-1518.CrossRefPubMed
36.
Thomas NA, Neville PJ, Baxter SW, Campbell IG: Genetic analysis of benign ovarian tumors. Int J Cancer J Int Du Cancer. 2003, 105 (4): 499-505.CrossRef
37.
Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM: BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010, 177 (4): 1611-1617.CrossRefPubMedPubMedCentral
38.
Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, et al: Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anti-cancer Drugs. 2011, 22 (9): 913-918.CrossRefPubMed
39.
Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T: Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol Off J United States Can Acad Pathol Inc. 2011, 24 (7): 1015-1022.CrossRef
40.
Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA: Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol. 2009, 33 (12): 1823-1832.CrossRefPubMedPubMedCentral
41.
Marchoudi N, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie-biologie. 2013
42.
Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K: KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. British J Cancer. 2008, 99 (12): 2020-2028.CrossRef
43.
Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, et al: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004, 202 (3): 336-340.CrossRefPubMed
44.
Emerson RE, Wang M, Liu F, Lawrence WD, Abdul-Karim FW, Cheng L: Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2007, 26 (4): 387-394.CrossRef
45.
Gu J, Roth LM, Younger C, Michael H, Abdul-Karim FW, Zhang S, Ulbright TM, Eble JN, Cheng L: Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst. 2001, 93 (15): 1147-1152.CrossRefPubMed
46.
Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC: Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst. 1992, 84 (23): 1793-1798.CrossRefPubMed
47.
Khalique L, Ayhan A, Whittaker JC, Singh N, Jacobs IJ, Gayther SA, Ramus SJ: The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer J Int Du Cancer. 2009, 124 (7): 1579-1586.CrossRef
48.
Kupryjanczyk J, Thor AD, Beauchamp R, Poremba C, Scully RE, Yandell DW: Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol Off J United States Can Acad Pathol Inc. 1996, 9 (3): 166-173.
49.
Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC: Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res. 1998, 58 (11): 2328-2330.PubMed
Metadata
Title
KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants
Authors
Sabine Heublein
Katinka Grasse
Harald Hessel
Alexander Burges
Miriam Lenhard
Jutta Engel
Thomas Kirchner
Udo Jeschke
Doris Mayr
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-483

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Characterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities

Research article

MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells

Research article

Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer

Research article

Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study

Research article

Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Study protocol

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits